122 related articles for article (PubMed ID: 36332669)
1. Hypomethylation of RPTOR in peripheral blood is associated with very early-stage lung cancer.
Zhu Q; Qiao R; Di F; Song Y; Zhang J; Xu T; Wang Y; Dai L; Gu W; Han B; Yang R
Clin Chim Acta; 2022 Dec; 537():173-180. PubMed ID: 36332669
[TBL] [Abstract][Full Text] [Related]
2. RPTOR methylation in the peripheral blood and breast cancer in the Chinese population.
Yin Y; Lei S; Li L; Yang X; Yin Q; Xu T; Zhou W; Li H; Gu W; Ma F; Yang R; Zhang Z
Genes Genomics; 2022 Apr; 44(4):435-443. PubMed ID: 34767153
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA.
Tang Q; Holland-Letz T; Slynko A; Cuk K; Marme F; Schott S; Heil J; Qu B; Golatta M; Bewerunge-Hudler M; Sutter C; Surowy H; Wappenschmidt B; Schmutzler R; Hoth M; Bugert P; Bartram CR; Sohn C; Schneeweiss A; Yang R; Burwinkel B
Oncotarget; 2016 Sep; 7(39):64191-64202. PubMed ID: 27577081
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of DYRK4 in peripheral blood is associated with increased lung cancer risk.
Qiao R; Zhu Q; Di F; Liu C; Song Y; Zhang J; Xu T; Wang Y; Dai L; Gu W; Han B; Yang R
Mol Carcinog; 2023 Nov; 62(11):1745-1754. PubMed ID: 37530470
[TBL] [Abstract][Full Text] [Related]
5.
Li M; Qiao R; Zhong R; Wei Y; Wang J; Zhang Z; Wang L; Xu T; Wang Y; Dai L; Gu W; Han B; Yang R
Biomarkers; 2022 Feb; 27(1):79-85. PubMed ID: 34882057
[TBL] [Abstract][Full Text] [Related]
6. The Association Between RAPSN Methylation in Peripheral Blood and Early Stage Lung Cancer Detected in Case-Control Cohort.
Qiao R; Di F; Wang J; Wei Y; Zhang Y; Xu T; Wang Y; Gu W; Han B; Yang R
Cancer Manag Res; 2020; 12():11063-11075. PubMed ID: 33173339
[TBL] [Abstract][Full Text] [Related]
7. The Association Between
Qiao R; Li M; Zhong R; Wei Y; Wang J; Zhang Z; Wang L; Xu T; Wang Y; Dai L; Gu W; Han B; Yang R
Cancer Manag Res; 2021; 13():7919-7927. PubMed ID: 34703313
[TBL] [Abstract][Full Text] [Related]
8. Novel blood-based hypomethylation of SH3BP5 is associated with very early-stage lung adenocarcinoma.
Qiao R; Zhong R; Liu C; Di F; Zhang Z; Wang L; Xu T; Wang Y; Dai L; Gu W; Han B; Yang R
Genes Genomics; 2022 Apr; 44(4):445-453. PubMed ID: 34783986
[TBL] [Abstract][Full Text] [Related]
9. Identification of FUT7 hypomethylation as the blood biomarker in the prediction of early-stage lung cancer.
Qiao R; Di F; Wang J; Wei Y; Xu T; Dai L; Gu W; Han B; Yang R
J Genet Genomics; 2023 Aug; 50(8):573-581. PubMed ID: 36898609
[TBL] [Abstract][Full Text] [Related]
10. Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma.
Fang Y; Qu Y; Ji L; Sun H; Li J; Zhao Y; Liang F; Wang Z; Su J; Liu J; Dai L; Ouyang S
Clin Epigenetics; 2022 Dec; 14(1):167. PubMed ID: 36463240
[TBL] [Abstract][Full Text] [Related]
11. Comparison and combination of blood DNA methylation at smoking-associated genes and at lung cancer-related genes in prediction of lung cancer mortality.
Zhang Y; Breitling LP; Balavarca Y; Holleczek B; Schöttker B; Brenner H
Int J Cancer; 2016 Dec; 139(11):2482-92. PubMed ID: 27503000
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
[TBL] [Abstract][Full Text] [Related]
13. [Peripheral blood
Zang Z; Qiao R; Zhu Q; Zhou X; Gu W; Han B; Yang R
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Mar; 43(3):349-359. PubMed ID: 37087578
[TBL] [Abstract][Full Text] [Related]
14. The association between
Li J; Zhou X; Li L; Ji L; Li J; Qu Y; Wang Z; Zhao Y; Zhang J; Liang F; Liu J; Gu W; Yang R; Ma F; Dai L
Front Oncol; 2023; 13():1148635. PubMed ID: 37274256
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and associated gene expression in blood prior to lung cancer diagnosis in the Norwegian Women and Cancer cohort.
Sandanger TM; Nøst TH; Guida F; Rylander C; Campanella G; Muller DC; van Dongen J; Boomsma DI; Johansson M; Vineis P; Vermeulen R; Lund E; Chadeau-Hyam M
Sci Rep; 2018 Nov; 8(1):16714. PubMed ID: 30425263
[TBL] [Abstract][Full Text] [Related]
16. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA.
Wang L; Aakre JA; Jiang R; Marks RS; Wu Y; Chen J; Thibodeau SN; Pankratz VS; Yang P
J Thorac Oncol; 2010 Jun; 5(6):778-85. PubMed ID: 20421821
[TBL] [Abstract][Full Text] [Related]
17. Epigenome-wide scan identifies differentially methylated regions for lung cancer using pre-diagnostic peripheral blood.
Zhao N; Ruan M; Koestler DC; Lu J; Marsit CJ; Kelsey KT; Platz EA; Michaud DS
Epigenetics; 2022 Apr; 17(4):460-472. PubMed ID: 34008478
[TBL] [Abstract][Full Text] [Related]
18. Methylation status of the PPP1R13L promoter region among lung cancer patients and healthy controls. Analytical cross-sectional study.
Yin J; Ma Y; Vogel U; Wang C; Zhang Y; Wang H
Sao Paulo Med J; 2019 Aug; 137(3):255-261. PubMed ID: 31483011
[TBL] [Abstract][Full Text] [Related]
19. Individual and joint contributions of genetic and methylation risk scores for enhancing lung cancer risk stratification: data from a population-based cohort in Germany.
Yu H; Raut JR; Schöttker B; Holleczek B; Zhang Y; Brenner H
Clin Epigenetics; 2020 Jun; 12(1):89. PubMed ID: 32552915
[TBL] [Abstract][Full Text] [Related]
20. Significance of screening sensitive methylation sites using whole-genome sequencing in early diagnosis of non-small cell lung cancer.
Zhang Y; Lu N; Pu S; Mu K
Cell Mol Biol (Noisy-le-grand); 2022 Feb; 67(5):218-226. PubMed ID: 35818250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
